Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

Persistent induction of goblet cell differentiation in the airways: Therapeutic approaches

© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus...

Full description

Bibliographic Details
Main Authors: Reid, A.T., Veerati, P.C., Gosens, R., Bartlett, N.W., Wark, P.A., Grainge, C.L., Stick, S.M., Kicic, Anthony, Moheimani, F., Hansbro, P.M., Knight, D.A.
Format: Journal Article
Language:English
Published: PERGAMON-ELSEVIER SCIENCE LTD 2018
Subjects:
Science & Technology
Life Sciences & Biomedicine
Pharmacology & Pharmacy
Goblet cell
Asthma
COPD
Cystic fibrosis
Mucus
Epithelium
Signaling pathways
Therapeutic
micro-RNA
Mechanical stress
Monoclonal antibody therapy
GROWTH-FACTOR RECEPTOR
BRONCHIAL EPITHELIAL-CELLS
RECOMBINANT HUMAN INTERLEUKIN-5
OBSTRUCTIVE PULMONARY-DISEASE
RESPIRATORY SYNCYTIAL VIRUS
COLONY-STIMULATING FACTOR
CYSTIC-FIBROSIS
MUCUS OVERPRODUCTION
NEBULIZED AMILORIDE
MUCIN PRODUCTION
Online Access:http://hdl.handle.net/20.500.11937/76808
Description
Summary:© 2017 Dysregulated induction of goblet cell differentiation results in excessive production and retention of mucus and is a common feature of several chronic airways diseases. To date, therapeutic strategies to reduce mucus accumulation have focused primarily on altering the properties of the mucus itself, or have aimed to limit the production of mucus-stimulating cytokines. Here we review the current knowledge of key molecular pathways that are dysregulated during persistent goblet cell differentiation and highlights both pre-existing and novel therapeutic strategies to combat this pathology.

Similar Items